Hasil Pencarian  ::  Simpan CSV :: Kembali

"Latar belakang: Pneumonia adalah salah satu masalah kesehatan utama pada geriatri. Proses penuaan sistem organ dan faktor komorbid banyak berperan pada peningkatan morbiditas dan mortalitas pneumonia pada pasien geriatri sehingga menyebabkan tingginya biaya pengobatan penyakit tersebut. Salah satu biaya yang menyerap besar anggaran rumah sakit adalah biaya antibiotik. Tingginya biaya penggunaan antibotik untuk pneumonia komunitas menyebabkan perlunya dilakukan analisis farmakoekonomi. Cost effectiveness adalah salah satu metode analisis farmakoekonomi. Tujuan: Menilai cost effectiveness tata laksana pneumonia komunitas pada geriatri. Metode: Penelitian ini dilakukan secara retrospektif pada pasien geriatri rawat inap dengan pneumonia komunitas di RSCM periode 1 Januari 2012-31 Maret 2016. Analisis cost effectiveness digunakan untuk analisis farmakoekonomi yang membandingkan biaya (cost) dengan hasil luaran klinis sembuh (effectiveness). Hasil: Sebanyak 104 pasien geriatri dengan pneumonia komunitas dirawat di RSCM dianalisis cost effectiveness dan dikelompokkan menjadi 5 kelompok yaitu: kombinasi seftriakson azitromisin (n=38), kombinasi sefotaksim azitromisin (n=23), monoterapi meropenem (n=22), kombinasi meropenem levofloksasin (n=13), dan monoterapi sefepim (n=8). Kesembuhan tertinggi pada monoterapi sefepim (100%), kombinasi sefotaksim azitromisin (95,7%), dan kombinasi seftriakson azitromisin (92,1%). Kematian tertinggi pada kombinasi meropenem levofloksasin (46,2%) dan monoterapi meropenem (36,4%). Penelitian ini dibagi menjadi 2 kelompok besar. Kelompok 1 terdiri dari kombinasi seftriakson azitromisin dan kombinasi sefotaksim azitromisin. Kelompok 2 terdiri dari kombinasi meropenem levofloksasin, monoterapi meropenem dan monoterapi sefepim. Nilai ACER (Average Cost Effectiveness Ratio) pada kombinasi seftriakson azitromisin Rp285.097,- dan monoterapi sefepim memiliki nilai ACER Rp 1.747.356,-. Pada nilai ICER (Intremental Cost Effectivenees Ratio), penggunaan kombinasi seftriakson azitromisin memberikan selisih penambahan harga sebesar Rp 31.756,- untuk setiap selisih penambahan 1% kesembuhan dibandingkan dengan kombinasi sefotaksim azitromisin. Penggunaan monoterapi sefepim memberikan selisih penurunan harga sebesar Rp 58.124,- untuk setiap selisih penambahan 1% kesembuhan dibandingkan dengan monoterapi meropenem. Penggunaan monoterapi sefepim memberikan selisih penurunan harga sebesar Rp 83.918,- untuk setiap selisih penambahan 1% kesembuhan dibandingkan dengan kombinasi meropenem levofloksasin. Penggunaan meropenem memberikan selisih penurunan harga sebesar Rp 179.724,- untuk setiap selisih penambahan 1% kesembuhan dibandingkan dengan kombinasi meropenem levofloksasin untuk terapi pneumonia komunitas pada geriatri. Kesimpulan: Kedua rejimen antibiotik kombinasi seftriakson azitromisin dan kombinasi sefotaksim azitromisin memiliki cost effectiveness yang sama untuk terapi pneumonia komunitas pada geriatri. Monoterapi sefepim memiliki cost effectiveness lebih tinggi dibandingkan monoterapi meropenem dan kombinasi meropenem levofloksasin untuk terapi pneumonia komunitas pada geriatri.

---

Background: Pneumonia is one of the major health problems in elderly. The aging process of organ systems and many comorbid factors contribute to increase the morbidity and mortality of pneumonia in geriatric patients, causing high costs of the treatment, mainly the cost of antibiotic. The high cost of antibiotic used for community pneumonia creates need for pharmacoeconomics analysis. Cost effectiveness analysis is one of the method for doing pharmacoeconomics analysis.

Objective: To analyze the cost effectiveness of antibiotic uses on community pneumonia in elderly.

Method: This study was conducted retrospectively in hospitalized geriatric patients with community pneumonia in RSCM for period of 1 January 2012-31 March 2016. The cost effectiveness analysis method was used to analyze pharmacoeconomics by comparing the expense (cost) with clinically cured patients (effectiveness).

Result: A total of 104 geriatric patients with community pneumonia treated in RSCM were analyzed by using cost effectiveness method. They were classified into 5 groups: combination of azithromycin ceftriaxone+azithromycin (n=23), combination of cefotaxime+azithromycin (n=38), meropenem monotherapy (n=22), combination of meropenem+levofloxacin (n=13), and cefepime monotherapy (n=8). The highest percentage of recovery was found in cefepime monotherapy (100%), followed by combination of cefotaxime+azithromycin (95.7%) and combination of ceftriaxone+azithromycin (92.1%). The highest percentage of mortality was observed in the combination of meropenem+ levofloxacin (46.2%), followed by meropenem monotherapy (36.4%). This research is divided into two large groups. Group 1 consisted of combination of ceftriaxone+azithromycin and combination of cefotaxime+azithromycin. Group 2 consisted of combination of meropenem+levofloxacin, meropenem monotherapy and cefepime monotherapy .The Average Cost Effectiveness Ratio of combination ceftriaxone+azithromycin is Rp 285.097,-while the ACER of cefepime monotherapy is Rp 1.747.356,-. The Intremental Cost Effectivenees Ratio of combination of ceftriaxone+azithromycin is Rp 31.756,- for each 1% increment of recovery when compared to combination of cefotaxime+azithromycin. The use of cefepime monotherapy provides reduction of Rp 58.124, - for each 1% additional of recovery compared to meropenem monotherapy. The use of cefepime monotherapy provides reduction of Rp 83.918,- for each 1% additional of recovery compared to combination of meropenem+levofloxacin. The use of meropenem provides reduction of Rp 179.724,- for each 1% additional of recovery compared to combination of meropenem+levofloxacin for treatment of community pneumonia in elderly.

Conclusions: Both of two regimen azithromycin+ceftriaxone and cefotaxime+azithromycin got the same cost of effectiveness for the treatment of community pneumonia in elderly. Cefepime monotherapy has higher cost effectiveness than meropenem monotherapy and combination of meropenem+levofloxacin for treatment of community pneumonia in elderly."

"Pneumonia komunitas merupakan peradangan akut pada parenkim paru yang bersumber dari masyarakat dengan tingkat mortalitas, morbiditas, dan beban biaya yang tinggi terutama pada pasien rawat inap. Rata-rata biaya yang dibutuhkan bagi pasien pneumonia komunitas di Indonesia dalam satu periode rawat inap kurang-lebih mencapai Rp11.877.120. Pemilihan antibiotik empiris yang tepat penting dalam mengendalikan infeksi dan mengurangi beban total biaya pengobatan. Studi farmakoekonomi digunakan untuk mengetahui intervensi antibiotik yang paling unggul dari aspek efektivitas-biaya. Penelitian ini bertujuan untuk menganalisis efektivitas-biaya levofloksasin monoterapi dibandingkan dengan kombinasi seftriakson-azitromisin pada pasien pneumonia komunitas rawat inap non-ICU di RSUD Tangerang Selatan. Desain studi yang digunakan merupakan cross-sectional dengan metode pengumpulan data secara retrospektif terhadap data rekam medis, data penggunaan obat, dan data billing. Efektivitas terapi dinilai sebagai proporsi pasien yang mencapai kestabilan klinis setelah 72 jam penggunaan antibiotik. Data biaya yang digunakan berupa data biaya medis langsung berdasarkan perspektif rumah sakit. Sampel pada penelitian ini berjumlah 86 pasien yang merupakan 43 pasien dari masing-masing kelompok terapi. Hasil penelitian menunjukkan adanya perbedaan bermakna antara efektivitas kelompok levofloksasin dan kombinasi seftriakson-azitromisin (p < 0,05). Berdasarkan perhitungan REB (rasio efektivitas-biaya), kelompok levofloksasin memiliki nilai sebesar Rp78.028,22/% efektivitas dan kelompok kombinasi seftriakson-azitromisin Rp107.666,91/% efektivitas.

---

Community-acquired pneumonia (CAP) is an acute inflammation of the lung parenchyma that originates from the community and carries a high mortality, morbidity, and cost burden, particularly in hospitalized patients. The average cost of treating CAP patients in Indonesia during a single hospitalization period is Rp11,877,120. Selecting the appropriate empiric antibiotic is crucial in controlling the infection and reducing the overall treatment costs. Pharmacoeconomic studies are conducted to determine the most effective and cost-efficient antibiotic intervention. This study aims to analyze the cost-effectiveness of levofloxacin monotherapy compared to the combination of ceftriaxone-azithromycin in non-ICU inpatient CAP cases at RSUD Tangerang Selatan. The study design was cross-sectional, utilizing a retrospective data collection method that involved medical records, drug usage data, and billing information. The therapy's effectiveness was assessed by the proportion of patients who achieved clinical stability after 72 hours of antibiotic use. The cost data utilized represents direct medical costs from the hospital's perspective. The study sample consisted of 86 patients, with 43 patients in each treatment group. The results indicated a significant difference in the effectiveness of the levofloxacin group compared to the ceftriaxone-azithromycin combination (p < 0.05). Calculation of the Average Cost-Effectiveness Ratio (ACER) revealed that the levofloxacin group had a value of Rp78,028.22 per % effectiveness, while the ceftriaxone-azithromycin combination group had a value of Rp107,666.91 per % effectiveness. "

"Rumah Sakit Karya Bhakti Pratiwi menggunakan seftriakson dan levofloksasin sebagai pilihan terapi utama berdasarkan pengalaman klinis pada pasien pneumonia komunitas dewasa rawat inap. Perbedaan biaya antara kedua obat ini menjadi alasan berlangsungnya penelitian ini. Tujuan penelitian ini adalah melakukan analisis efektivitas-biaya AEB dari seftriakson dan levofloksasin sehingga diperoleh pengobatan yang lebih efektif-biaya. Penelitian ini menggunakan desain cross-sectional dengan data sekunder berupa data peresepan dan data administrasi biaya pasien pneumonia rawat inap tahun 2017 yang berasal dari Sistem Informasi Rumah Sakit. Pengambilan sampel menggunakan teknik total sampling. Sampel yang dilibatkan pada penelitian ini sebanyak 33 pasien, yaitu 23 pasien menggunakan seftriakson dan 10 pasien menggunakan levofloksasin. Efektivitas pengobatan diukur berdasarkan lama hari rawat. Biaya diperoleh dari median total biaya pengbatan yang berasal dari biaya obat utama, biaya obat lain, biaya obat penyakit penyerta, biaya alat kesehatan, biaya laboratorium, biaya radiologi, biaya fisioterapi, biaya pelayanan, biaya administrasi, dan biaya rawat inap. Berdasarkan hasil penelitian, rata-rata lama hari rawat pasien yang menggunakan seftriakson adalah 3,43 hari dan levofloksasin 3,50 hari dan tidak terdapat perbedaan signifikan pada analisis Mann-Whitney p=0,440. Median total baya pengobatan seftriakson sebesar Rp2.183.356,54 lebih murah dibandingkan levofloksasin Rp2.819.895,56. Seftriakson secara umum memiliki nilai REB sebesar Rp636.547,10/hari lebih efektif-biaya dibandingkan levofloksasin dengan nilai REB: Rp805.684,40/hari.

---

Karya Bhakti Pratiwi Hospital has been using ceftriaxone and levofloxacin as the empirical therapy option in community acquired pneumonia in adult patients. The difference in the cost between these two drugs encouraged researcher to perform Cost effectiveness analysis CEA to obtain more cost effective treatment. The study design was a cross sectional, data were collected retrospectively with total sampling method using data from the prescribing data and administrative financial data of inpatient pneumonia in 2017 from Hospital Information System. The number of samples were 33 patients, consisted of 23 patients using ceftriaxone and 10 patients using levofloxacin.

The effectiveness of treatment has measured by the length of stay. The total costs therapy were obtained from the median total cost from major drug costs, other drug costs, medical equipment costs, laboratory costs, radiology costs, physiotherapy costs, service fees cost, administrative costs, and hospitalization costs. Based on the results of the study, the efficacy of ceftriaxone with an average length of stay was 3.43 days and levofloxacin 3.50 days. The median total costs therapy of ceftriaxone was cheaper Rp2,183,356.54 than levofloxacin Rp2,819,895.56. The result shows that ceftriaxone generally REB Rp 636.547,10 day more cost effective than levofloxacin REB Rp805,684.40 day."

"Penyakit pneumonia adalah salah satu penyebab utama kematian pada anak di dunia. Kasus kematian anak di Indonesia yang diakibat oleh pneumonia diperkirakan mencapai 23,6 . Antibiotik memiliki peran penting dalam terapi pengobatan pneumonia. Pemberian ampisilin dan seftriakson direkomendasikan untuk pasien pneumonia anak. Analisis Efektivitas Biaya AEB merupakan salah satu metode farmakoekonomi untuk mengetahui obat yang efektif dengan biaya terkecil. Penelitian ini dilakukan untuk membandingkan total biaya medis langsung dan efektivitas yang ditinjau dari lama hari rawat pasien yang menggunakan ampisilin dan seftriakson. Desain penelitian yang digunakan adalah non eksperimental dengan studi penelitian cross sectional. Pengambilan data dilakukan secara retrospektif terhadap data sekunder pasien dan data keuangan pasien pneumonia anak di Rumah Sakit Anak dan Bunda Harapan Kita Jakarta Tahun 2016. Pengambilan sampel dilkakukan secara total sampling. Jumlah pasien dalam analisis sebanyak 21 pasien, yaitu 8 pasien menggunakan ampisilin dan 13 pasien menggunakan seftriakson. Median total biaya medis antara ampisilin dan seftriakson berturut-turut sebesar Rp 2.717.075,00 dan. Rp 3.333.750,00. Median lama hari rawat ampisilin dan seftriakson berturut-turut 5,5 hari dan 6 hari. Berdasarkan AEB menunjukkan bahwa ampisilin lebih cost-effective dibandingkan seftriakson.

---

Pneumonia is one of the leading causes of death in children in the world. The case of child mortality in Indonesia caused by pneumonia is estimated at 23.6 . Antibiotics have an important role in the treatment of pneumonia therapy. Provision of ampicillin and ceftriaxone is recommended for pediatric pneumonia patients. Cost Effectiveness Analysis AEB is one of the pharmacoeconomic methods to find out the effective drug with the smallest cost. This study was conducted to compare the total direct medical cost and effectiveness, which was measured from length of stay LOS , of ampicillin and ceftriaxone usage. The research design used was non experimental with cross sectional study. Retrospective data retrieval was performed on patient secondary data and financial data of child pneumonia patient at Rumah Sakit Anak dan Bunda Harapan Kita Jakarta in 2016. Samples were taken by using total sampling method. The number of patients in the analysis were 21 patients, which included 8 patients with ampicillin and 13 patients with ceftriaxone. Median total medical costs between ampicillin and ceftriaxone were respectively Rp 2,717,075.00 and. Rp 3,333,750.00. Median duration of day of ampicillin and ceftriaxone consecutive 5.5 days and 6 days. An AEB shows that ampicillin is more cost effective than ceftriaxone. "

"ABSTRAKPneumonia komunitas merupakan salah satu penyakit infeksi yang umum terjadi danmerupakan salah satu penyebab kematian dan kesakitan terbanyak. Penyakit ini memilikidampak terhadap sosioekonomi dimana tingginya biaya kesehatan terutama disebabkanoleh biaya rawat inap. Evaluasi farmakoekonomi dilaksanakan untuk menilai efektivitasbiaya antibiotik untuk mengetahui apakah pengobatan antibiotik memberikan outcometerapi yang baik dengan biaya yang minimal. Penelitian dilakukan terhadap kombinasiseftriakson-azitromisin dan levofloksasin tunggal sebagai antibiotik empiris untuk pasienpneumonia rawat inap. Analisis efektivitas biaya dilakukan dengan membandingkan totalbiaya medis langsung dan efektivitas yang dilihat dari lama rawat masing-masingkelompok pengobatan. Penelitian dilakukan di RSUP Persahabatan, Jakarta, dengandesain penelitian studi kohort retrospektif, dimana pengambilan data dilakukan secararetrospektif terhadap data sekunder, berupa rekam medis pasien dari tahun 2014-2016.Jumlah pasien yang dilibatkan dalam analisis 100 pasien, yaitu 64 pasien menggunakanantibiotik seftriakson iv dan azitromisin oral, dan 36 pasien menggunakan levofloksasiniv tunggal. Median biaya antibiotik berbeda signifikan antara kelompok seftriaksonazitromisindan kelompok levofloksasin, yaitu Rp.130.756,- dan Rp.286.952,-. Medianbiaya medis langsung kelompok seftriakson-azitromisin lebih tinggi dibandingkankelompok levofloksasin tunggal, yaitu Rp. 6.494.998,- dan Rp. 5.444.242,-. Keberhasilanterapi kelompok seftriakson-azitromisin yaitu 95,3 , sementara keberhasilan terapikelompok levofloksasin sebesar 97,2 namun tidak terdapat perbedaaan signifikan.Median lama rawat LOS dan lama rawat terkait antibiotik LOSAR kelompoklevofloksasin berturut-turut sebesar 6 hari dan 5 hari, lebih singkat dibandingkan LOSdan LOSAR kelompok seftriakson-azitromisin, yaitu 7 hari dan 6 hari. Nilai ACERkelompok levofloksasin sebesar Rp.56.011,-/persen efektivitas lebih rendahdibandingkan kelompok seftriakson-azitromisin sebesar Rp. 68.153,-/persen efektivitas.Berdasarkan hasil penelitian disimpulkan bahwa levofloksasin lebih cost-effectivedibanding kombinasi seftriakson-azitromisin.

---

ABSTRACTCommunity Acquired Pneumonia CAP is one of the most common infectious diseasesand is one of the leading causes of death and morbidity. This disease has an impact onsocioeconomic where the high cost of health is mainly caused by the cost ofhospitalization. A pharmacoeconomic evaluation was conducted to assess the costeffectivenessof antibiotics to find out whether antibiotic treatment results in a goodtherapeutic outcome with a minimal cost. The study was conducted on a combination ofceftriaxone azithromycin and single levofloxacin as an empirical antibiotic for inpatientCAP patients. Cost effectiveness analysis is conducted by comparing the total directmedical costs and the effectiveness measured from length of stay of each treatmentgroup. The study was conducted in RSUP Persahabatan, Jakarta, with a cohortretrospective design study, where retrospective data retrieval was conducted onsecondary data, in the form of patient medical records from 2014 2016. The number ofpatients involved in the analysis of 100 patients, ie 64 patients using combination of ivceftriaxone and oral azithromycin, and 36 patients using single iv levofloxacin. Medianantibiotic costs differed significantly between the ceftriaxone azithromycin group andthe levofloxacin group, which were Rp.130,756, and Rp.286,952, . Median directmedical costs of the ceftriaxone azithromycin group were higher than the singlelevofloxacin group, which was Rp. 6,494,998, and Rp. 5,444,242, . Success rate ofgroup of ceftriaxone azithromycin group was 95.3 , while the success rate oflevofloxacin group was 97.2 but there was no significant difference. Median length ofstay LOS and length of stay antibiotic related LOSAR of levofloxacin group wererespectively 6 days and 5 days, shorter than LOS and LOSAR of ceftriaxoneazithromycingroup, which were 7 days and 6 days. The value of the ACER levofloxacingroup was Rp.56.011, percent effectiveness, lower than the ceftriaxone azithromycingroup of Rp. 68.153, percent effectiveness. Based on the results of the study, it isconcluded that levofloxacin is more cost effective than a combination of ceftriaxoneazithromycin."

"Penyakit tonsilofaringitis termasuk dalam infeksi saluran pernafasan akut yang kasusnya banyak di masyarakat, mencapai 40 - 60 % kunjungan pasien ke Puskesmas. Dari Sistim Pencatatan dan Pelaporan Terpadu Puskesmas menunjukkan bahwa tonsilofaringitis adalah yang paling sering ditemui di lapangan.Dilain pihak pengobatan antibiotika irasional terus berlangsung, tidak terkecuali ISPA. Padahal menurut laporan WHO, kebanyakan penyakit ISPA disebabkan oleh virus bukan bakteri, hanya 10 % gejala ISPA yang memang betul-betul memerlukan antibiotika.Sementara DepKes RI mengeluarkan pedoman Pengobatan Dasar Berdasar Gejala bagi Puskesmas, dimana faringitis oleh infeksi kuman ditetapkan pilihan I amoksisilin, pilihan II ampisilin, pilihan III penisilin V dan terakhir pilihan IV eritromisinOleh karena itu perlu adanya evaluasi dengan cost effectiveness analysis antara amoksisilin dan eritromisin pada terapi tonsilofaringitis, agar diketahui pilihan yang tepat secara ekonomis di masyarakat.Penelitian dilakukan di daerah Jakarta Barat pada Puskesmas Tambora, mulai bulan Juni sampai dengan September 2002.Dalam evaluasi disertakan faktor-faktor yang berhubungan dengan kesembuhan terapi tonsilofaringitis mulai internal umur, jenis kelamin, pendidikan, status gizi, penghasilan keluarga, kepatuhan minum obat, adanya pengaruh minum obat simptomatis sebelumnya, ada tidaknya efek samping obat dan eksternal terpapar oleh polusi ditempat kerja, kepadatan hunian rumah serta kondisi lingkungan rumah.Desain penelitian kohort, perhitungan sampel uji beda dua mean. Jumlah sampel jadi 241 orang dengan rincian 120 orang menerima pengobatan dengan amoksisilin dan 121 orang menerima pengobatan dengan eritromisin. Jugs dilakukan pemeriksaan kultur kuman dan tes resistensi terhadap 75 spesimen swap, sebagai kontrol terhadap proses terapi yang rasional. Keduanya sensitif, namun eritromisin lebih sensitif dari amoksisilin.Hasil kesembuhan penderita tonsilofaringitis dari 120 orang penderita yang diterapi amoksisilin: 101 (84,2%) orang penderita yang sembuh dan dari 121 orang yang diterapi eritromisin 115 (95,0%) orang penderita yang sembuh. Dalam analisa statistik nilai p = 0,005 bermakna, yang berarti bahwa kesembuhan dipengaruhi oleh adanya perbedaan jenis antibiotika yang digunakan dan nilai RR = 8,007, yang berarti kesembuhan dengan terapi eritromisin lebih baik 8.007 kali dibanding amoksisilin.Berdasarkan perhitungan akhir, unit cost untuk amoksisilin Rp. 182.405,97, lebih murah dibanding eritromisin, yaitu Rp. 156.834,90. Maka terapi tonsilofaringitis yang menggunakan antibiotika eritromisin lebih cost effective dibanding dengan terapi yang menggunakan amoksisilin.

---

Cost Effectiveness Analysis Between Amoxicillin And erythromycin for The Tonsilopharyngftis Therapies at Puskesmas Tambora, West Jakarta 2002. Tonsilopharyngitis is one of the acute respiratory infection cases which frequently found in society. In fact, 40-60% patients who come to the Puskesmas are infected. The Integrated Reporting and Recording System of Puskesmas shows that tonsilopharyngitis is the most commonly case found in the society.

On the other hand, the irrational antibiotic treatment, including ISPA, is continuously conducted. According to WHO, most of the ISPA diseases are mainly caused by virus rather than bacteria. Only 10 % of ISPA symptoms need antibiotic.

Depkes RI has published a guidance of the basic treatment based on symptoms, which are given for the Puskesmas. It is stated that the pharyngitis caused by a germ infection determined as option 1 amoxicillin, option II ampicillin, and option III penicillin V and option IV erythromycin.

The techniques of cost effectiveness analysis between the amoxicillin and erythromycin for the tonsilopharyngitis are done in order to know the right use of therapy in the society economically.

The research is held at Puskesmas Tambora located in west Jakarta started from June until September 2002.

It is included in the evaluation the factors which related to the convalescence of the tonsilopharyngitis therapy antibiotic. The internal factors, namely, education, nutrition status, family income, medicine consumption, the previous effect of the symptomatic medicine consumption, the existence of the side effect of the medicine, and the external factors are air pollution in the workplace, thickness of the habitation and the environment condition.

Cohort research design is the sample test of the two different means. There are 241 patients for the sample. 120 of them are given with the amoxicillin therapy and the other 121 patients are given with the erythromycin therapy. The culture examination of the germ and the resistance test for the 785-swap specimen are also conducted as the control of the rational therapy. Both of the used antibiotics are still sensitive for the tonsilopharyngitis germ, and the erythromycin is more sensitive rather than amoxicillin.

The tonsilopharyngitis healing result of the 120 patients who have given the amoxicillin therapy consists of 101 (84,2%) patients, and 115 (95%) out of the 121 patients who have given the erythromycin therapy are recuperated. In a statistic analysis, p= 0.005 is valuable. It means that the recuperation is influenced by the different kinds of antibiotic used, and RR = 8,007, which has a recovery meaning for the therapy is 8.007 times better than amoxicillin.

Based on the final calculation, unit cost for the amoxicillin is Rp 182.405,97 and for the erythromycin is RP 156.834,90. Thus, tonsilopharyngitis therapy, which is using erythromycin, is more cost effective rather than the tonsilopharyngitis therapy using amoxicillin"

"Hipertensi dan diabetes melitus menjadi salah satu faktor risiko kejadian kardiovaskuler. Tidak terkontrolnya hipertensi dapat menyebabkan perburukan kesehatan dan ekonomi pada penderitanya. Kombinasi terapi antihipertensi dinilai adekuat untuk mencapai target tekanan darah <140/90 mmHg. Obat antihipertensi golongan ACEI, ARB, dan CCB merupakan terapi yang sesuai untuk pasien dengan diabetes melitus tipe 2 dan harganya bervariasi. Penelitian sebelumnya menunjukkan bahwa golongan ARB lebih cost-effective dibandingkan yang lainnya. Tujuan penelitian ini adalah untuk menganalisis efektivitas biaya dari kombinasi terapi amlodipin-kandesartan dibandingkan dengan amlodipin-ramipril pada pasien hipertensi dengan diabetes melitus tipe 2. Penelitian cross-sectional ini dilakukan di RSUPN dr. Cipto mangunkusumo dengan menggunakan rekam medis pasien tahun 2017-2019. Subjek penelitian yang memenuhi kriteria inklusi sebanyak 87 pasien. Pasien dibagi menjadi dua kelompok: kelompok yang mendapat terapi amlodipin-kandesartan dan kelompok yang mendapat terapi amlodipin-ramipril. Analisis efektivitas biaya diperoleh dari perhitungan biaya medik langsung, menghitung efektivitas terapi berdasarkan jumlah pasien yang mencapai target tekanan darah <140/90 mmhg, serta menghitung nilai ACER. Kombinasi amlodipin-kandesartan memiliki efektivitas terapi 48.9%, sedangkan efektivitas terapi amlodipin-ramipril 45,2%. Nilai ACER kelompok amlodipin-kandesartan dan kelompok amlodipin-ramipril adalah Rp. 1.604.736,2 per efektivitas and Rp 1.811.278,8 per efektivitas. Dapat disimpulkan bahwa amlodipin-kandesartan lebih cost-effective dibandingkan amlodipin-ramipril.

---

Hypertension and diabetes mellitus are risk factors for cardiovascular events. Uncontrolled hypertension can cause health and economic burdens in patients. The combination of antihypertensive therapy is considered adequate to achieve the targeted blood pressure <140/90 mmHg. Antihypertensive drugs class such as ACEIs, ARBs, and CCBs are appropriated therapies for patients with type 2 diabetes mellitus and the price differences. Previous studies have shown that the ARBs are more cost-effective than others. The aim of this study was to analyze the cost-effectiveness of combination of amlodipine-candesartan compared to amlodipine-ramipril in hypertensive patients with type 2 diabetes mellitus. This cross-sectional study was conducted at Dr. Cipto Mangunkusumo Hospital by using patient medical records in 2017-2019. Research subjects who met the inclusion criteria were 87 patients. Patients were divided into two groups: group receiving amlodipine-candesartan and group receiving amlodipine-ramipril. Cost effectiveness analysis obtained from the calculation of direct medical costs, calculated the effectiveness of therapy based on the number of patients who reached the target blood pressure <140/90 mmHg, and calculated the value of ACER. Amlodipine-candesartan has a therapeutic effectiveness of 48.9%, while the effectiveness of amlodipine-ramipril is 45.2%. The ACER value of the amlodipine-candesartan group and the amlodipine-ramipril group were Rp 1,604,736.2 per effectiveness and Rp 1,811,278.8per effectiveness. To conclude, amlodipine-candesartan is more cost-effective than amlodipine-ramipril."

"Community-Acquired Pneumonia CAP adalah penyakit sistem pernapasan yang menyerang jaringan parenkim paru. Penyakit ini banyak mengancam individu dewasa dengan penurunan sistem imun. Penderita CAP mengalami peningkatan setiap tahunnya akibat peningkatan polusi udara yang berada di wilayah perkotaan, terutama pada kawasan industri. Penderita CAP akan mengalami peningkatan produksi sputum yang berujung pada kesulitan dalam mengeluarkan sputum. Pasien dengan CAP sering mengalami penurunan refleks batuk yang membuat sputum terakumulasi di jalan napas sehingga menyebabkan peningkatan usaha untuk bernapas. Fisioterapi dada merupakan salah satu teknik pembersihan jalan napas pada pasien dengan penurunan refleks batuk. Karya Ilmiah Akhir Ners ini bertujuan untuk menganalisis intervensi fisioterapi dada untuk mengurangi gejala serta mencegah perburukan pada pasien dengan CAP. Metodologi yang digunakan adalah metode studi kasus dan analisa penelitian yang telah ada. Hasil analisa yang didapatkan menunjukkan fisioterapi dada dapat menurunkan usaha napas pasien, pengurangan episode demam, perubahan karakteristik sputum, serta penuruan persentase mortalitas melalui skoring CURB-65.

---

Community Acquired Pneumonia CAP is a respiratory disease that attacks the pulmonary parenchymal tissue. This disease threatens many adults with decreased immune system. CAP sufferers are increasing every year due to increasing air pollution in urban areas, especially in industrial areas. CAP sufferers will experience an increase in sputum production that leads to difficulties in removing sputum. Patients with CAP often have decreased cough reflexes that make sputum accumulate in the airway causing increased effort to breathe. Chest physiotherapy is one of the airway cleansing techniques in patients with decreased cough reflexes.

This Final Scientific Work of Ners aims to analyze the interventions of chest physiotherapy to reduce symptoms and prevent worsening of patients with CAP. The methodology used is the case study method and the existing research analysis. The results obtained showed chest physiotherapy can decrease the patient 39 s breathing effort, reduction of febrile episodes, changes in sputum characteristics, as well as the percentage of mortality by scoring CURB 65."

"[ABSTRAKLatar Belakang : Pasien usia lanjut seringkali memerlukan rawat inap karena infeksi pneumonia yang disertai dengan penurunan status fungsional. Hubungan antara penurunan status fungsional pada pasien usia lanjut dengan pneumonia komunitas yang dirawat inap dengan kesintasan belum banyak diteliti.Tujuan : Mendapatkan informasi mengenai perbedaan kesintasan 30-hari pasien pneumonia komunitas berusia lanjut dengan berbagai derajat ketergantungan. Metodologi : Penelitian kohort retrospektif berbasis analisis kesintasan terhadap pasien usia lanjut dengan pneumonia komunitas di ruang rawat akut geriatri RSCM periode Januari 2010-Desember 2013. Dilakukan ekstraksi data dari rekam medik mengenai status fungsional, kondisi klinis dan faktor perancu, kemudian dicari data mortalitasnya dalam 30 hari. Status fungsional awal perawatan dinilai dengan indeks ADL Barthel, kemudian dikelompokkan menjadi tiga kelompok, yaitu mandiri-ketergantungan ringan, ketergantungan sedang-berat dan ketergantungan total. Perbedaan kesintasan antara ketiga kelompok ditampilkan dalam kurva Kaplan Meier. Perbedaan kesintasan antara ketiga kelompok diuji dengan Log-rank test, dengan batas kemaknaan <0,05. Analisis multivariat dengan Cox?s proportional hazard regression untuk menghitung adjusted hazard ratio (dan interval kepercayaan 95%-nya) dengan koreksi terhadap variabel perancu.Hasil : Dari 392 subjek, sebanyak 79 subjek (20,2%) meninggal dunia dalam waktu 30 hari. Rerata kesintasan seluruh subjek 25 hari (IK95% 24,66-26,49), kelompok mandiri-ketergantungan ringan 28 hari (IK95% 27,38-29,46), ketergantungan sedang-berat 25 hari (IK95% 23,71-27,25), ketergantungan total 23 hari (IK95% 21,46-24,86). Kesintasan 30-hari pada kelompok mandiri- ketergantungan ringan 92,1% (SE 0,029), ketergantungan sedang-berat 80,2% (SE 0,046), ketergantungan total 68,0% (SE 0,041). Crude HR pada ketergantungan sedang-berat 2,68 (p=0,008; IK95% 1,29-5,57), ketergantungan total 4,32 (p<0,001; IK95% 2,24-8,31) dibandingkan dengan mandiri-ketergantungan ringan. Setelah dilakukan adjustment terhadap variabel perancu didapatkan fully adjusted HR pada kelompok ketergantungan total 3,82 (IK95% 1,95-7,51), ketergantungan sedang-berat 2,36 (IK 95% 1,13-4,93).Simpulan : Terdapat perbedaan kesintasan 30-hari pasien pneumonia komunitas berusia lanjut pada berbagai derajat ketergantungan; semakin berat derajat ketergantungan, semakin buruk kesintasan 30-harinya.

---

ABSTRACTBackground : Elderly patients often require hospitalization because of pneumonia accompanied by decreased functional status. The relationship between the declines in functional status in elderly patients with community acquired pneumonia who are hospitalized with survival rate has not been widely studied. Objective : To determine the difference of 30-days survival in elderly patients with community-acquired pneumonia in various degree of dependency during admission.Method : A retrospective cohort study based on survival analysis of the elderly patients with community-acquired pneumonia in acute geriatric ward RSCM from January 2010 to December 2013. Extraction of data from medical records regarding functional status, clinical conditions and confounding factors, then followed up the 30-day mortality. Functional status at the start of hospitalization was assessed by the ADL Barthel index, then grouped into three, which are independent-mild dependence, moderate-severe dependence and total dependence. The difference of survival rate among the three groups is shown in the Kaplan- Meier curves. The difference in survival rate among the three groups were tested with the log-rank test, with a significance limit of <0.05. Multivariate analysis with Cox's proportional hazards regression to calculate adjusted hazard ratio (and its 95% confidence interval) with correction for confounding variables.Results : Of the 392 subjects, a total of 79 subjects (20.2%) died within 30 days. The mean survival rate of all subjects was 25 days (95%CI 24.66-26.49), independent-mild dependence group was 28 days (95%CI 27.38-29.46), moderate-severe dependence group was 25 days (95%CI 23,71-27.25), the total dependence group was of 23 days (95%CI 21.46-24.86). The 30-day survival of independent-mild dependence group was 92.1% (SE 0.029), moderate-severe dependence group was 80.2% (SE 0.046), total dependence group was 68.0% (SE 0.041). Crude HR of moderate-severe dependence group was 2.68 (p=0.008; 95%CI 1.29-5.57), the total dependence group was 4.32 (p<0.001; 95%CI 2.24- 8.31) compared with independent-mild dependence group. After adjustment for confounding variables, obtained the fully adjusted HR was 3,82 (95%CI 1,95- 7,51) in total dependence group, and 2,36 (95%CI 1,13-4,93) in moderate-severe dependence group.Conclusion : There are differences in 30-day survival rate of elderly patients with community-acquired pneumonia in various degrees of dependence; the more severe the degree of dependence, the worse its 30-day survival rate.;Background : Elderly patients often require hospitalization because of pneumonia accompanied by decreased functional status. The relationship between the declines in functional status in elderly patients with community acquired pneumonia who are hospitalized with survival rate has not been widely studied. Objective : To determine the difference of 30-days survival in elderly patients with community-acquired pneumonia in various degree of dependency during admission.Method : A retrospective cohort study based on survival analysis of the elderly patients with community-acquired pneumonia in acute geriatric ward RSCM from January 2010 to December 2013. Extraction of data from medical records regarding functional status, clinical conditions and confounding factors, then followed up the 30-day mortality. Functional status at the start of hospitalization was assessed by the ADL Barthel index, then grouped into three, which are independent-mild dependence, moderate-severe dependence and total dependence. The difference of survival rate among the three groups is shown in the Kaplan- Meier curves. The difference in survival rate among the three groups were tested with the log-rank test, with a significance limit of <0.05. Multivariate analysis with Cox's proportional hazards regression to calculate adjusted hazard ratio (and its 95% confidence interval) with correction for confounding variables.Results : Of the 392 subjects, a total of 79 subjects (20.2%) died within 30 days. The mean survival rate of all subjects was 25 days (95%CI 24.66-26.49), independent-mild dependence group was 28 days (95%CI 27.38-29.46), moderate-severe dependence group was 25 days (95%CI 23,71-27.25), the total dependence group was of 23 days (95%CI 21.46-24.86). The 30-day survival of independent-mild dependence group was 92.1% (SE 0.029), moderate-severe dependence group was 80.2% (SE 0.046), total dependence group was 68.0% (SE 0.041). Crude HR of moderate-severe dependence group was 2.68 (p=0.008; 95%CI 1.29-5.57), the total dependence group was 4.32 (p<0.001; 95%CI 2.24- 8.31) compared with independent-mild dependence group. After adjustment for confounding variables, obtained the fully adjusted HR was 3,82 (95%CI 1,95- 7,51) in total dependence group, and 2,36 (95%CI 1,13-4,93) in moderate-severe dependence group.Conclusion : There are differences in 30-day survival rate of elderly patients with community-acquired pneumonia in various degrees of dependence; the more severe the degree of dependence, the worse its 30-day survival rate.;Background : Elderly patients often require hospitalization because of pneumonia accompanied by decreased functional status. The relationship between the declines in functional status in elderly patients with community acquired pneumonia who are hospitalized with survival rate has not been widely studied. Objective : To determine the difference of 30-days survival in elderly patients with community-acquired pneumonia in various degree of dependency during admission.Method : A retrospective cohort study based on survival analysis of the elderly patients with community-acquired pneumonia in acute geriatric ward RSCM from January 2010 to December 2013. Extraction of data from medical records regarding functional status, clinical conditions and confounding factors, then followed up the 30-day mortality. Functional status at the start of hospitalization was assessed by the ADL Barthel index, then grouped into three, which are independent-mild dependence, moderate-severe dependence and total dependence. The difference of survival rate among the three groups is shown in the Kaplan- Meier curves. The difference in survival rate among the three groups were tested with the log-rank test, with a significance limit of <0.05. Multivariate analysis with Cox's proportional hazards regression to calculate adjusted hazard ratio (and its 95% confidence interval) with correction for confounding variables.Results : Of the 392 subjects, a total of 79 subjects (20.2%) died within 30 days. The mean survival rate of all subjects was 25 days (95%CI 24.66-26.49), independent-mild dependence group was 28 days (95%CI 27.38-29.46), moderate-severe dependence group was 25 days (95%CI 23,71-27.25), the total dependence group was of 23 days (95%CI 21.46-24.86). The 30-day survival of independent-mild dependence group was 92.1% (SE 0.029), moderate-severe dependence group was 80.2% (SE 0.046), total dependence group was 68.0% (SE 0.041). Crude HR of moderate-severe dependence group was 2.68 (p=0.008; 95%CI 1.29-5.57), the total dependence group was 4.32 (p<0.001; 95%CI 2.24- 8.31) compared with independent-mild dependence group. After adjustment for confounding variables, obtained the fully adjusted HR was 3,82 (95%CI 1,95- 7,51) in total dependence group, and 2,36 (95%CI 1,13-4,93) in moderate-severe dependence group.Conclusion : There are differences in 30-day survival rate of elderly patients with community-acquired pneumonia in various degrees of dependence; the more severe the degree of dependence, the worse its 30-day survival rate., Background : Elderly patients often require hospitalization because of pneumonia accompanied by decreased functional status. The relationship between the declines in functional status in elderly patients with community acquired pneumonia who are hospitalized with survival rate has not been widely studied. Objective : To determine the difference of 30-days survival in elderly patients with community-acquired pneumonia in various degree of dependency during admission.Method : A retrospective cohort study based on survival analysis of the elderly patients with community-acquired pneumonia in acute geriatric ward RSCM from January 2010 to December 2013. Extraction of data from medical records regarding functional status, clinical conditions and confounding factors, then followed up the 30-day mortality. Functional status at the start of hospitalization was assessed by the ADL Barthel index, then grouped into three, which are independent-mild dependence, moderate-severe dependence and total dependence. The difference of survival rate among the three groups is shown in the Kaplan- Meier curves. The difference in survival rate among the three groups were tested with the log-rank test, with a significance limit of <0.05. Multivariate analysis with Cox's proportional hazards regression to calculate adjusted hazard ratio (and its 95% confidence interval) with correction for confounding variables.Results : Of the 392 subjects, a total of 79 subjects (20.2%) died within 30 days. The mean survival rate of all subjects was 25 days (95%CI 24.66-26.49), independent-mild dependence group was 28 days (95%CI 27.38-29.46), moderate-severe dependence group was 25 days (95%CI 23,71-27.25), the total dependence group was of 23 days (95%CI 21.46-24.86). The 30-day survival of independent-mild dependence group was 92.1% (SE 0.029), moderate-severe dependence group was 80.2% (SE 0.046), total dependence group was 68.0% (SE 0.041). Crude HR of moderate-severe dependence group was 2.68 (p=0.008; 95%CI 1.29-5.57), the total dependence group was 4.32 (p<0.001; 95%CI 2.24- 8.31) compared with independent-mild dependence group. After adjustment for confounding variables, obtained the fully adjusted HR was 3,82 (95%CI 1,95- 7,51) in total dependence group, and 2,36 (95%CI 1,13-4,93) in moderate-severe dependence group.Conclusion : There are differences in 30-day survival rate of elderly patients with community-acquired pneumonia in various degrees of dependence; the more severe the degree of dependence, the worse its 30-day survival rate.]"

"Community acquired pneumonia (CAP) oleh patogen resisten obat (PRO) memiliki tingkat keparahan yang tinggi. CAP akibat PRO memerlukan terapi antibiotik spektrum luas, skor Drugs Resistance in Pneumonia (DRIP) mampu memprediksi kasus tersebut. Penggunaan skor DRIP dapat mencegah kegagalan terapi antibiotik empirik dan mempersingkat lama rawatan, untuk itu diperlukan validasi. Penelitian ini merupakan studi Cohort Retrospektif pada pasien CAP yang dirawat inap selama periode Januari 2019 hingga Juni 2020. Data diambil dari rekam medis, kegagalan antibiotik bila terdapat kematian, pindah rawat ICU dan eskalasi antibiotik. Performa skor DRIP dianalisis dengan menentukan nilai kalibrasi dan diskriminasi, uji Hosmer-Lemeshow dan Area Under Curve (AUC). Diperoleh 480 pasien yang telah memenuhi kriteria. Terdapat 331 pasien (69%) dengan skor DRIP <4 dan 149 pasien (31%) dengan skor DRIP ≥4, dengan jumlah kegagalan antibiotik sebesar 283 pasien (59%), 174 pasien (61,4%) skor DRIP <4 dan 109 pasien (38,5%) skor DRIP ≥4. Kalibrasi DRIP menggunakan uji Hosmer-Lemeshow diperoleh p-value = 0,667 (p>0,05), diskriminasi AUC pada kurva ROC diperoleh 0,651 (IK 95%; 0,601-0,700). Skor DRIP menunjukkan performa yang cukup baik dalam memprediksi kegagalan antibiotic empiric pada pasien CAP yang terinfeksi PRO. Skor DRIP tidak berhubungan dengan lama rawatan di Rumah Sakit.

---

Community-acquired pneumonia (CAP) caused by drug resistant pathogens (DRP) has a high level of severity. The incidence of CAP due to DRP requires broad spectrum antibiotic therapy, the Drugs Resistance in Pneumonia (DRIP) score is able to predict these cases. The use of the DRIP score can prevent antibiotic failure and minimize length of hospitalization, but validation is needed . This research is a retrospective cohort study in CAP patients who were hospitalized during the period January 2019 to June 2020. Data were taken from patient medical records, and failure of empiric antibiotics occurs when one of this criteria are found: patient mortality, ICU transfer and escalation of antibiotics as well as length of stay. Furthermore, the performance of the DRIP score was analyzed by determining the calibration and discrimination, using the Hosmer-Lemeshow test and the Area Under Curve (AUC). There were 480 patients who met the criteria. There were 331 patients (69%) with a DRIP score <4 and 149 patients (31%) with a DRIP score ≥4, with a total of 283 patients (59%) of antibiotic failures which were detailed in 174 patients (61.4%) with a DRIP score <4 and 109 patients (38.5%) DRIP score ≥4. DRIP calibration using the Hosmer-Lemeshow test obtained p-value=0.667 (p>0.05), AUC observations on the ROC curve obtained 0.651 (95% CI; 0.601-0.700). The DRIP score showed good performance in predicting failure of empiric antibiotics in infected CAP patients. PRO. The DRIP score is not related to the length of stay in the hospital."